PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Mol Cancer Ther. Author manuscript; available in PMC 2011 September 1.
Published in final edited form as:
Mol Cancer Ther. 2010 September; 9: 2637.
doi:  10.1158/1535-7163.MCT-10-0671
PMCID: PMC2993116
NIHMSID: NIHMS231534

Correction: ErbB-Inhibitory Protein: A Modified Ectodomain of Epidermal Growth Factor Receptor Synergizes with Dasatinib to Inhibit Growth of Breast Cancer Cells

Correction: ErbB-Inhibitory Protein: A Modified Ectodomain of Epidermal Growth Factor Receptor Synergizes with Dasatinib to Inhibit Growth of Breast Cancer Cells

In this article ( Mol Cancer Ther 2010;9:1503–14), which was published in the June 1, 2010 issue of Molecular Cancer Therapeutics (1), the labels of Figs. 1B and C were not aligned correctly. The correct Figure 1 appears here. The online article has been changed to reflect this correction and no longer matches the print.

References

1. Nautiyal J, Yu Y, Aboukameel A, et al. ErbB-inhibitory protein: A modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells. Mol Cancer Ther. 2010;9:1503–14. [PMC free article] [PubMed]